Evidence map›Paper›PMID 37070487›Full record

ArticleAnnals of medicine2023

Optimal combination of immune checkpoint and senescence molecule predicts adverse outcomes in patients with acute myeloid leukemia.

Peipei Wang, Yuling Zhang, Qinghua Cai, Qingqin Long, Shiyi Pan, Wei Zhou, Tingfen Deng, Wenjian Mo, Shunqing Wang, Yuping Zhang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. High percentage of bone marrow CD8Blood science (Baltimore, Md.) · 2024
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Peipei WangDepartment of Oncology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, P.R. China.ORCID 0000-0001-7201-4928
Yuling ZhangDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, P.R.China.ORCID 0000-0002-5761-1633
Qinghua CaiDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, P.R.China.ORCID 0000-0001-8682-8383
Qingqin LongDepartment of Oncology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, P.R. China.
Shiyi PanDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, P.R.China.
Wei ZhouDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, P.R.China.
Tingfen DengDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, P.R.China.
Wenjian MoDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, P.R.China.
Shunqing WangDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, P.R.China.
Yuping ZhangDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, P.R.China.ORCID 0000-0003-1055-2071
Caixia WangDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, P.R.China.ORCID 0000-0002-7895-1813
Cunte ChenDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, P.R.China.ORCID 0000-0003-3733-9174
Guangzhou First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh expression of immune checkpoints (ICs) and senescence molecules (SMs) contributes to T cell dysfunction, tumor escape, and progression, but systematic evaluation of them in co-expression patterns and prognosis in acute myeloid leukemia (AML) was lacking.

methodsThree publicly available datasets (TCGA, Beat-AML, and GSE71014) were first used to explore the effect of IC and SM combinations on prognosis and the immune microenvironment in AML, and bone marrow samples from 68 AML patients from our clinical center (GZFPH) was further used to validate the findings.

resultsHigh expression of CD276, Bcl2-associated athanogene 3 (BAG3), and SRC was associated with poor overall survival (OS) of AML patients. CD276/BAG3/SRC combination, standard European Leukemia Net (ELN) risk stratification, age, and French-American-British (FAB) subtype were used to construct a nomogram model. Interestingly, the new risk stratification derived from the nomogram was better than the standard ELN risk stratification in predicting the prognosis for AML. A weighted combination of CD276 and BAG3/SRC positively corrected with

conclusionHigh expression of ICs and SMs was associated with poor OS of AML patients. The co-expression patterns of CD276 and BAG3/SRC might be potential biomarkers for risk stratification and designing combinational immuno-targeted therapy in AML.Key MessagesHigh expression of CD276, BAG3, and SRC was associated with poor overall survival of AML patients.The co-expression patterns of CD276 and BAG3/SRC might be potential biomarkers for risk stratification and designing combinational immuno-targeted therapy in AML.

Indexed as

Leukemia, Myeloid, AcuteAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsB7 AntigensCD8-Positive T-LymphocytesHumansMutationPrognosisTumor MicroenvironmentAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsB7 AntigensBAG3 protein, humanCD276 protein, humanacute myeloid leukemiaimmune checkpointPrognosisrisk stratificationsenescence

Identifiers

PMID37070487
PMCPMC10120552
OpenAlexW4366236978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.